Skip to main content
SpringerLink
Log in

Drug-Nutrient Interactions in the Elderly

  • Chapter
Handbook of Drug-Nutrient Interactions

Part of the book series: Nutrition and Health ((NH))

Abstract

The elderly are more prone to experience drug-nutrient interactions (DNIs) given their higher use of medication, chronic and cumulative disorders, and the likelihood of marginal nutritional state. The elderly, arbitrarily defined as those 65 yr of age and older, constitute approx 14% of the US population. By the year 2030, the elderly cohort will grow to approx 20% of the nation’s population, with the “old-old” cohort, aged 85 yr and older, being the most rapidly growing segment of the population (1). Elder adults are the most heterogeneous population with respect to physical, social, and health status (2). The rate at which an individual ages is variable, and how well an individual ages is also variable, being dependent on both genetic and environmental factors (2). For instance, one 75-yr-old gentleman may be viewed as being a frail elder if he is suffering from chronic disease and disability, whereas another 75-yr-old gentleman may be viewed as having aged “successfully” if he has limited disease and disability (3,4). Frailty refers to a loss of physiologic reserve that makes a person susceptible to disability from minor stresses (5). Rockwood and colleagues evaluated the many different proposed definitions of frailty by different authors and suggest that any definition that is used must include multisystem impairment, instability, change over time, an association with aging, and an associated increased risk of adverse outcome (6). Successful aging has been described as a process by which deleterious effects are minimized and function is preserved (4). Therefore, chronological age is not as descriptive as physiological age when assessing the health status of an individual.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. http://www.eire.census.gov./popest/archives/national/nation2/intfile2–1.txt Accessed 11/21/02.

    Google Scholar 

  2. Oskvig RM. Special problems in the elderly. Chest 1999; 115 (5): 158–164.

    Article  Google Scholar 

  3. Simonson W. Introduction to the aging process. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly ( 3rd ed. ). Harvey Whitney Books, Cincinnati, OH, 2001, pp. 1–39.

    Google Scholar 

  4. Basics of geriatric care: biology of aging. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 3–9.

    Google Scholar 

  5. Basics of geriatric care: prevention of disease and disability. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 46–53.

    Google Scholar 

  6. Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. Drugs Aging 2000; 17 (4): 295–302.

    Article  CAS  Google Scholar 

  7. Devone CAJ. Comprehensive geriatric assessment: making the most of the aging years. Curr Opin Clin Nutr Metab Care 2002; 5: 19–24.

    Article  Google Scholar 

  8. Lassila HC, Stoehr GP, Ganguli M, et al. Use of prescription medications in an elderly rural population: the MoVIES project. Ann Pharmacother1996; 30: 589–595.

    Google Scholar 

  9. S aini A, Birrer R, Harghel C, et al. Polyharmacy, complementary and alternative medicine in the elderly. PandT 2001;26(12):616–620, 627.

    Google Scholar 

  10. Delafeunte JC. Perspectives on geriatric pharmacotherapy. Pharmacotherapy 199 1; 11(3):222–224.

    Google Scholar 

  11. Basics of geriatric care:demographics. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics (3rd ed.). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 9–23.

    Google Scholar 

  12. Baum C, Kennedy DL, Forbes MB, et al. Drug use in the United States in 1981. JAMA 1984; 25: 1293–1297.

    Article  Google Scholar 

  13. Coons JS, Johnson M, Chandler MHH. Sources of self-treatment information and use of home remedies and over-the-counter medications among older adults. J Geriatr Drug Ther 1992; 7: 71–82.

    Google Scholar 

  14. Chen LH, Liu S, Cook-Newell ME, Barnes K. Survey of drug use by the elderly and possible impact of drugs on nutritional status. Drug-Nutr Interact 1985; 3: 73–86.

    CAS  Google Scholar 

  15. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287: 337–344.

    Article  Google Scholar 

  16. Guidelines abstracted from consensus recommendations for the management of chronic heart failure. J Am Geriatr Soc 2000; 48: 1521–1524.

    Google Scholar 

  17. The use of oral anticoagulants in older people. J Am Geriatr Soc 2000; 48: 224–27.

    Google Scholar 

  18. Mendelson G, Ness J, Aranow WS. Drug treatment of hypertension in older persons in an academic hospital-based geriatrics practice.J Am Geriatr Soc1999; 47: 97–599.

    Google Scholar 

  19. Gattis WA, Larsen RL, Hasselblad V. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure. Am Heart J 1998; 136: 43–48.

    Article  CAS  Google Scholar 

  20. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy 1999; 19 (11): 1296–1307.

    Article  CAS  Google Scholar 

  21. Pahor M, Shorr JI, Somes GW, et al. Diuretic-based treatment and cardiovascular events in patients with mild renal dysfunction enrolled in the systolic hypertension in the elderly program. Arch Intern Med 1998; 158: 1340–1345.

    Article  CAS  Google Scholar 

  22. Smith NL, Psaty BM, Pitt B, et al. Temporal patterns in the medical treatment of congestive heart failure with angiotensin-converting enzyme inhibitors in older adults, 1989 through 1995. Arch Intern Med 1998; 158: 1074–1080.

    Article  CAS  Google Scholar 

  23. Krumholz HA, Radford MJ, Wang Y, et al. Early beta-blocker therapy for acute myocardial infarction in elderly patients. Ann Intern Med 1999; 131: 648–654.

    Article  CAS  Google Scholar 

  24. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998; 280 (7): 623–629.

    Article  CAS  Google Scholar 

  25. Avorn J, Soumerai SB, Everitt DE, et al. A randomized trial of a program to reduce the use of psychoactive medications in a nursing home. N Engl J Med 1992; 327: 168–173.

    Article  CAS  Google Scholar 

  26. Tobias DE, Pulliam CC. General and psychotherapeutic medication use in 878 nursing homes: a 1997 national survey. Consult Pharm 1997; 12: 1401–1408.

    Google Scholar 

  27. Beers MH, Baran RW, Frenia K. Drugs and the elderly, part 1: the problems facing managed care. Am J Manag Care 2000; 6: 1313–1320.

    CAS  Google Scholar 

  28. Hanlon JT, Fillenbaum GG, Ruby CM, et al. Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging 2001; 18 (2): 123–131.

    Article  CAS  Google Scholar 

  29. Fanning KD, Ruby CM, Twersky JI, et al. The prevalence of dietary supplement and home remedy use by patients in a geriatric outpatient clinic. Consult Pharm 2002; 17 (11): 972–978.

    Google Scholar 

  30. Anderson DL, Shane-McWhorter L, Crouch BI, et al. Prevalence and patterns of alternative medication use in a university hospital outpatient clinic serving rheumatology and geriatric patients. Pharmacotherapy 2000; 20 (8): 958–966.

    Article  CAS  Google Scholar 

  31. Dolder C, Lacro J, Dolder N, et al. Alternative medication use: results of a survey of older veterans. Consult Pharm 2002; 17: 653–662.

    Google Scholar 

  32. Zeilmann CA, Dole EJ, Skipper BJ, et al. Use of herbal medicine by elderly Hispanic and non-hispanic white patients. Pharmacotherapy 2003; 23 (4): 526–532.

    Article  Google Scholar 

  33. Anderson DL, Shane-McWhorter L, Crouch BI, et al. Prevalence and patterns of alternative medication use in a university hospital outpatient clinic serving rheumatology and geriatric patients. Pharmacotherapy 2000; 20 (8): 958–966.

    Article  CAS  Google Scholar 

  34. Palisso G, Di Maro G, Galzerano D, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. Am J Clin Nutr 1994; 59: 1291–1296.

    Google Scholar 

  35. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA 2002; 288: 715–721.

    CAS  Google Scholar 

  36. Ly J, Percy L, Dhanani S. Use of dietary supplements and their interactions with prescription drugs in the elderly. Am J Health-Syst Pharm 2002; 59: 1759–1762.

    CAS  Google Scholar 

  37. Marinac JS, Buchinger C, Godfrey L, et al. Vitamin and mineral supplement use among older Americans. Pharmacotherapy 2001; 21: 1268–1269.

    Google Scholar 

  38. Zeilmann CA, Dole EJ, Skipper B, et al. Herb use in Anglo and Hispanic elders. Pharmacotherapy 1999; 19: 1204.

    Google Scholar 

  39. Williams ME. Clinical implications of aging physiology. Am J Med 1984; 76: 1048–1054.

    Article  Google Scholar 

  40. Canto JG, Fincher C, Kiefe CI. Atypical presentations among Medicare beneficiaries with unstable angina pectoris. Am J Cardiol 2002; 90 (3): 248–253.

    Article  Google Scholar 

  41. Strand LM, Morley PC, Cipolle RJ, et al. Drug-related problems: their structure and function. DICP 1990; 24 (11): 1093–1097.

    CAS  Google Scholar 

  42. Hanlon JT, Shimp LA, Semla TP. Recent advances in geriatrics: drug-related problems in the elderly. Ann Pharmacother 2000; 34: 360–365.

    Article  CAS  Google Scholar 

  43. Hanlon JT, Gray SL, Schmader KE.Adverse drug reactions. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly ( 3rd ed. ). Harvey Whitney Books, Cincinnati, OH, 2001, pp. 289–314.

    Google Scholar 

  44. Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol 1992; 32: 897–904.

    Article  CAS  Google Scholar 

  45. ASHP guidelines on adverse drug reaction monitoring and reporting. Am J Health-Syst Pharm 1995; 52: 417–419.

    Google Scholar 

  46. Venulet J, Ham MT. Methods for monitoring and documenting adverse drug reactions. Int J Clin Pharmacol Ther 1996; 34 (3): 112–129.

    CAS  Google Scholar 

  47. Karch FE, Lasagna L. Adverse drug reactions—a critical review. JAMA 1975; 234: 1236–1241.

    Article  CAS  Google Scholar 

  48. Kessler DA. Introducing MedWatch, using FDA form 3500, a new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765–2768.

    Article  CAS  Google Scholar 

  49. Nolan L, O’Malley K. Prescribing for the elderly Part1: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–149.

    CAS  Google Scholar 

  50. Fields TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med 2001; 161 (3): 1629–1634.

    Article  Google Scholar 

  51. Montamat SC, Cusack B. Overcoming problems with polypharmacy and drug misuse in the elderly. Clin Geriatr Med 1992; 8 (1): 143–158.

    CAS  Google Scholar 

  52. Grymonpre RE, Mitenko PA, Sitar DS, et al. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc 1988; 36: 1092–1098.

    CAS  Google Scholar 

  53. Fouts M, Hanlon J, Pieper C, et al. Identification of elderly nursing facility residents at high risk for drug-related problems. Consult Pharm 1997; 12: 1103–1111.

    Google Scholar 

  54. Schneider JK, Mion LC, Frengley D. Adverse drug reactions in an elderly outpatient population. Am J Hosp Pharm 1992; 49: 90–96.

    CAS  Google Scholar 

  55. Thomas EJ, Brennan TA. Incidence and types of preventable adverse events in elderly patients: population based review of medical records. BMJ 2000; 320: 741–744.

    Article  CAS  Google Scholar 

  56. Beers MH. Aging as a risk factor for medication-related problems. Consult Pharm1999;14(12): 1337–1340.

    Google Scholar 

  57. Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945–948.

    CAS  Google Scholar 

  58. Chrischilles EA, Segar ET, Wallace RB. Self-reported adverse drug reactions and related resource use. Ann Intern Med 1992; 117: 634–640.

    Article  CAS  Google Scholar 

  59. Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996; 44: 194–197.

    CAS  Google Scholar 

  60. Budden F. Adverse drug reactions in long term care facility residents. J Am Geriatr Soc 1985; 33: 449–450.

    CAS  Google Scholar 

  61. Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc 1993; 41: 1326–1332.

    CAS  Google Scholar 

  62. Bates DW, Leape LL, Petrycki S, et al. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8: 289–294.

    Article  CAS  Google Scholar 

  63. B ootman JL, Harrison DL, Cox E. The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 1997; 157: 2089–2096.

    Article  CAS  Google Scholar 

  64. Johnson JA, Bootman JL. Drug-related morbidity and mortality: a cost-of-illness model. Arch Intern Med 1995; 155: 1949–1956.

    Article  CAS  Google Scholar 

  65. Hanlon JT, Shimp LA, Semla TP. Recent advances in geriatrics: drug-related problems in the elderly. Ann Pharmacother 2000; 34: 360–365.

    Article  CAS  Google Scholar 

  66. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157 (14): 1531–1536.

    Article  CAS  Google Scholar 

  67. Willcox SM, Himmelstein DU, Woolhandler S. Inappropriate drug prescribing for the community-dwelling elderly. JAMA 1994; 272: 292–296.

    Article  CAS  Google Scholar 

  68. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the national 1996 medical expenditure panel survey. JAMA 2001; 286: 2823–2829.

    Article  CAS  Google Scholar 

  69. Pitkala KH, Strandberg TE, Tilvis RS. Inapprorpiate drug rescribing in home-dwelling, elderly patients: a population-based survey. Arch Intern Med 2002; 162: 1707–1712.

    Article  Google Scholar 

  70. Aparasu RR, Sitzman SJ. Inappropriate prescribing for elderly outpatients. Am J Health Syst Pharm 1999; 56: 433–439.

    CAS  Google Scholar 

  71. Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse dug events in nursing homes. Am J Med 2000; 109: 87–94.

    Article  CAS  Google Scholar 

  72. Gurwitz JH, Rochon P. Improving the quality of medication use in elderly patients: a not-so-simple prescription. Arch Intern Med 2002; 162: 1670–1672.

    Article  Google Scholar 

  73. Lewis CW, Frongillo EA, Roe DA. Drug–nutrient interactions in three long-term-care facilities. J Am Diet Assoc 1995; 95: 309–315.

    Article  CAS  Google Scholar 

  74. Hanlon JT, Schmader KE, Boult C, et al. Use of inappropriate prescription drugs by older people. J Am Geriatr Soc 2002; 50: 26–34.

    Article  Google Scholar 

  75. Dhall J, Larrat P, Lapane KL. Use of potentially inappropriate drugs in nursing homes. Pharmacotherapy 2002; 22 (1): 88–96.

    Article  Google Scholar 

  76. Hanlon JT, Fillenbaum GG, Schmader KE, et al. Inappropriate drug use among community-dwelling elderly. Pharmacotherapy. 2000; 20 (5): 575–582.

    Article  CAS  Google Scholar 

  77. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 medical expenditure panel survey. JAMA 2001; 286: 2823–2829.

    Article  CAS  Google Scholar 

  78. Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc 1994; 42: 1241–1247.

    CAS  Google Scholar 

  79. Stuck AE, Beers MH, Steiner A, et al. Inappropriate medication use in community-residing older persons. Arch Intern Med 1994; 154: 2195–2200.

    Article  CAS  Google Scholar 

  80. Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med 1992; 117: 684–689.

    Article  CAS  Google Scholar 

  81. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992; 45 (10): 1045–1051.

    Article  CAS  Google Scholar 

  82. Samsa GP, Hanlon JT, Schmader KE, et al. A summated score for the medication appropiateness index: development and assessment of clinimetric properties including content validity. J Clin Epidemiol 1994; 47 (8): 891–896.

    Article  CAS  Google Scholar 

  83. Kenney RA. Physiology of Aging. Clin Geriatr Med 1985; 1 (1): 37–59.

    CAS  Google Scholar 

  84. Swift CG. Pharmacodynamics: changes in homeostatic mechanisms, receptor and target organ sensitivity in the elderly. Br Med Bull 1990; 46 (1): 36–52.

    CAS  Google Scholar 

  85. Psychiatric disorders: aging and mental health. In: Beers MH, Berkow R, eds. The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 307–341.

    Google Scholar 

  86. Neurologic disorders: aging and the nervous system. In: Beers MH, Berkow R, eds. The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 380–463.

    Google Scholar 

  87. Musculoskeletal disorders: aging and the musculoskeletal system. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 467–557.

    Google Scholar 

  88. Hematologic disorders and cancer: aging and the blood. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 672–752.

    Google Scholar 

  89. Pulmonary disorders: aging and the lungs. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 753–809.

    Google Scholar 

  90. Cardiovascular disorders: aging and the cardiovascular system. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 813–950.

    Google Scholar 

  91. Kidney and urinary tract disorders: aging and the kidney. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 951–996.

    Google Scholar 

  92. Gastrointestinal disorders: aging and the gastrointestinal tract. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 1000–1153.

    Google Scholar 

  93. Dermatological and sensory organ disorders: aging and the skin. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 1231–1350.

    Google Scholar 

  94. Infectious disease: aging and the immune system. In: Beers MH, Berkow R, eds.The Merck Manual of Geriatrics ( 3rd ed. ). Merck Research Laboratories, Whitehouse Station, NJ, 2000, pp. 1351–1382.

    Google Scholar 

  95. Berkey DB, Shay K. General dental care for the elderly. Clin Geriatr Med 1992; 8 (3): 579–597.

    CAS  Google Scholar 

  96. Altman DF. Changes in gastrointestinal, pancreatic, biliary, and hepatic function with aging. Gastroenterol Clin North Am. 1990; 19 (2): 227–234.

    CAS  Google Scholar 

  97. Hurwitz A, Brady DA, Schaal SE et al. Gastric acidity in older adults. JAMA 1997; 278 (8): 659–662.

    Article  CAS  Google Scholar 

  98. LeCouteur DG, McLean AJ. The aging liver: drug clearance and an oxygen diffusion barrier hypothesis. Clin Pharmacokinet 1998; 34: 359–373.

    Article  Google Scholar 

  99. O’Mahony D, O’Leary P, Quigley EMM. Aging and intestinal motility: a review of factors that affect intestinal motility in the aged. Drugs Aging 2002; 19 (7): 515–527.

    Article  Google Scholar 

  100. Pugh KG, Wei JY. Clinical implications of the physiological changes in the aging heart. Drugs Aging 2001; 18 (4): 263–276.

    Article  CAS  Google Scholar 

  101. Lichtenstein MJ. Hearing and visual impairments. Clin Geriatr Med 1992; 8 (1): 173–182.

    CAS  Google Scholar 

  102. Danziger RS, Tobin JD, Becker LC, et al. The age-associated decline in glomerular filtration in healthy normotensive volunteers: lack of relationship to cardiovascular performance. J Am Geriatr Soc 1990; 38: 1127–1132.

    CAS  Google Scholar 

  103. Hanlon JT, Ruby CM, Guay D et al. Geriatrics In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach ( 5rd ed. ). McGraw-Hill, New York, NY, 2002, pp. 79–89.

    Google Scholar 

  104. Crome P, Flanagan RJ. Pharmacokinetic studies in elderly people: are they necessary? Clin Pharmacokinet 1994; 26 (4): 243–247.

    Article  CAS  Google Scholar 

  105. Omran ML, Morley JE. Assessment of protein energy malnutrition in older persons, part I: history, examination, body composition and screening tools. Nutrition 2000; 16: 50–63.

    Article  CAS  Google Scholar 

  106. Roe DA. Geriatric nutrition. Clin Geriatr Med 1990; 6 (2): 319–334.

    CAS  Google Scholar 

  107. Chapron DJ. Drug disposition and response. In: Delafuente JC, Stewart RB, eds. Therapeutics in the Elderly ( 3rd ed. ). Harvey Whitney Books, Cincinnati, OH, 2001, pp. 257–288.

    Google Scholar 

  108. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321 (5): 303–321.

    Article  CAS  Google Scholar 

  109. Meyer BR. Renal function in aging. J Am Geriatr Soc 1989; 37: 791–800.

    CAS  Google Scholar 

  110. Rowe JW, Andres RA, Robin FD, et al. Age adjusted normal standards for creatinine in man. Ann Intern Med 1976; 84: 567–569. [letter]

    Google Scholar 

  111. Beck LH. The aging kidney: defending a delicate balance of fluid and electrolytes. Geriatrics 2000;55(4):26–28, 31–32.

    Google Scholar 

  112. http://www.fda.gov/cber/guidelines.htm Guidance for Industry. Content and Format for Geriatric Labeling. October 2001. Accessed 10/7/02

  113. Affrime M, Samir G, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet 2002; 41: 13–19.

    Article  CAS  Google Scholar 

  114. Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetic study of esomeprazole in the elderly. Clin Pharmacokinet. 2001; 40 (2): 145–150.

    Article  CAS  Google Scholar 

  115. Sproule B, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16 (3): 165–177.

    Article  CAS  Google Scholar 

  116. Hanratty CG, McGlinchey P, Johnston DG, et al. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 2000; 17 (5): 353–362.

    Article  CAS  Google Scholar 

  117. Jorgas KM, Sedek G, Fotteler B, et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997; 62 (3): 300–310.

    Article  Google Scholar 

  118. Solomon D, Gurwitz JH. Toxicity of nonsteroidal anti-inflammatory drugs in the elderly: is advanced age a risk factor? Am J Med 1997; 102: 208–215.

    Article  CAS  Google Scholar 

  119. Bennett WM. Guide to drug dosage in renal failure. Clin Pharmacokinet 1988; 15: 326–354.

    Article  CAS  Google Scholar 

  120. Lam YWF, Banerji S, Hatfield C, et al. Principles of drug administration in renal insufficiency. Clin Pharmacokinet 1997; 32 (1): 30–57.

    Article  CAS  Google Scholar 

  121. Appel HM. Coping with renal insufficiency in the elderly. Consult Pharm 2000; 15 (2): 127–133.

    Google Scholar 

  122. Hammerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35 (1): 49–64.

    Article  CAS  Google Scholar 

  123. Ensrud KE, Duong T, Cauley JA, et al. Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Ann Intern Med 2000; 132: 345–353.

    Article  CAS  Google Scholar 

  124. Charles P. Calcium absorption and calcium bioavailability. J Intern Med 1992; 231: 161–168.

    Article  CAS  Google Scholar 

  125. Chiu KM. Efficacy of calcium supplements on bone mass in postmenopausal women. J Gerontol: Med Sci 1998; 54 (A96): M275–M280.

    Google Scholar 

  126. Pattanaungkul S, Riggs BL, Yergey Al, et al. Relationship of intestinal calcium absorption to 1,25– dihydroxyvitamin D [1,23(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action. J Clin Endocrinol Metab 2000; 85 (11): 4023–4027.

    Article  CAS  Google Scholar 

  127. Holdsworth MT, Forman WB, Killilea TA, et al. Transdermal fentanyl disposition in elderly subjects. Gerontology 1994; 40: 32–37.

    Article  CAS  Google Scholar 

  128. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31–41.

    Article  Google Scholar 

  129. Abernethy DR. Altered pharmacodynamics of cardiovascular drugs and their relation to altered pharmacokinetics in elderly patients. Clin Geriatr Med 1990; 6 (2): 285–292.

    CAS  Google Scholar 

  130. Reidenberg MM, Kevy M, Warner H, et al. Relationship between diazepam dose, plasma level, age, and central nervous system depression. Clin Pharmacol Ther 1978; 23: 371–374.

    CAS  Google Scholar 

  131. Greenblat DL, Divoll M, Harmatz JS, et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981; 30: 475–486.

    Article  Google Scholar 

  132. Gurwitz JH, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901–904.

    Article  CAS  Google Scholar 

  133. Heinsimer JA, Lefkowitz RJ. The impact of aging on adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc 1985; 33 (3): 184–188.

    CAS  Google Scholar 

  134. www.fda.gov Guideline for Industry: Studies in Support of Special Populations: Geriatrics August 1994. Accessed 10/7/02

    Google Scholar 

  135. Antonicelli R, Omboni S, Giovanni DC, et al. Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24–hour ambulatory blood pressure monitoring. Drugs Aging 2002; 19 (7): 541–551.

    Article  CAS  Google Scholar 

  136. Neldam S, Forsen B. Antihypertensive treatment in elderly patients aged 75 years or over: a 24–week study of the tolerability of candesartan cilexetil in relation to hydrochlorothiazide. Drugs Aging 2001; 18 (3): 225–232.

    Article  CAS  Google Scholar 

  137. Morley JE. Anorexia of aging: physiologic and pathologic. Am J Clin Nutr 1997; 66: 760–773.

    CAS  Google Scholar 

  138. Corti MC, Guralnik JM, Salive ME, Sorkin JD. Serum albumin level and physical disability as predicotrs of mortality in older persons. JAMA 1994; 272: 1036–1042.

    Article  CAS  Google Scholar 

  139. Nutrition Screening Initiative. Nutrition Interventions Manual for Professionals Caring for Older Americans. Nutrition Screening Initiative, Washington, DC, pp. 1992.

    Google Scholar 

  140. Vellas B, Garry PJ, Guigoz Y, eds. Mini Nutritional Assessment (MNA): Research and Practice in the Elderly. Nestlé Nutrition Workshop Series, Clinical and Performance Programme, volume 1. S. Karger AG, Basel, Switzerland, 1999.

    Google Scholar 

  141. Vellas B, Lauque S, Andrieu S, et al. Nutrition assessment in the elderly. Curr Opin Clin Nutr Metab Care 2001; 4: 5–8.

    Article  CAS  Google Scholar 

  142. Sacks GS. Nutritional considerations. In: Delafuente JC, Stewart RB, eds. Therapeutics in the elderly ( 3rd ed. ). Harvey Whitney Books, Cincinnati, OH, 2001, pp. 599–626.

    Google Scholar 

  143. Morley JE, Silver AJ. Nutritional issues in nursing home care. Ann Intern Med 1995; 123: 850–859.

    Article  CAS  Google Scholar 

  144. High KP. Nutritional strategies to boost immunity and prevent infection in elderly individuals. Clin Infect Dis 2001; 33: 1892–1900.

    Article  CAS  Google Scholar 

  145. Aghdassi E, McArthur M, Liu B, et al. A comparison of the diet in a population of institutionalized Canadian elderly to the dietary reference intake. Am J Clin Nutr 2002; 75 (suppl): 339–340S.

    Google Scholar 

  146. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: clinical and nutritional aspects. Am J Respir Crit Care Med 1997; 156: 1908–1914.

    Article  CAS  Google Scholar 

  147. Cederholm T, Järgén C, Hellström K. Outcome of protein-energy malnutrition in elderly medical patients. Am J Med 1995; 98: 67–74.

    Article  CAS  Google Scholar 

  148. Morley JE. Anorexia, body composition, and ageing. Curr Opin Clin Nutr Metab Care 2001; 4: 9–13.

    Article  CAS  Google Scholar 

  149. Sharkey JR, Branch LG, Zohoori N, et al. Inadequate nutrient intakes among homebound elderly and their correlation with individual characteristics and health-related factors. Am J Clin Nutr 2002; 76: 1435–1445.

    CAS  Google Scholar 

  150. Janssen HCJP, Samson MM, Verhaar HJJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75: 611–615.

    CAS  Google Scholar 

  151. Bianchetti A, Rozzini R, Carabellese C, et al. Nutritional intake, socioeconomic conditions, and health status in a large elderly population. J Am Geriatr Soc 1990; 38: 521–526.

    CAS  Google Scholar 

  152. Campion EW. Home alone, and in danger. N Engl J Med 1996; 334: 1738–1739.

    Article  CAS  Google Scholar 

  153. Duthie SJ, Whalley LJ, Collins AR, et al. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002; 75: 908–913.

    CAS  Google Scholar 

  154. Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318: 1720–1728.

    Article  CAS  Google Scholar 

  155. Baik HW, Russell RM. Vitamin B12 deficiency in the elderly. Annu Rev Nutr 1999; 19: 357–377.

    Article  CAS  Google Scholar 

  156. Russell RM, Suter PM. Vitamin requirements of elderly people: an update. Am J Clin Nutr 1993; 58: 4–14.

    CAS  Google Scholar 

  157. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes. National Academy Press, Washington, DC, 1997, 1998, 2000, 2001, 2002.

    Google Scholar 

  158. Bates CJ, Walmsley CM, Prentice A, Finch S. Use of medicines by older people in a large British national survey, and their relation to vitamin status indices. Publ Health Nutr 1999; 2: 15–22.

    CAS  Google Scholar 

  159. Drinka PJ, Goodwin JS. Prevalence and consequences of vitamin deficiency in the nursing home: a critical review. J Am Geriatr Soc 1991; 39: 1008–1017.

    CAS  Google Scholar 

  160. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. J Am Geriatr Soc 1992; 40: 1197–1204.

    CAS  Google Scholar 

  161. Lindenbaum J, Rosenberg I, Wilson P, et al. Prevalence of cobalamin deficiency in the Framingham elderly population. Am J Clin Nutr 1994; 60: 2–11.

    CAS  Google Scholar 

  162. Kant AK, Moser-veillon PB, Reynolds RD. Effect of age on changes in plasma erythrocyte and urinary B-6 vitamers after an oral vitamin B-6 load. Am J Clin Nutr 1988; 48: 1284–1290.

    CAS  Google Scholar 

  163. Ferroli CE, Trumbo PR. Bioavailability of vitamin B-6 in young and older men. Am J Clin Nutr 1994; 60: 68–71.

    CAS  Google Scholar 

  164. Guilland JC, Bereski-Reguig B, Lequeu B, et al. Evaluation of pyridoxine intake and pyridoxine status among aged institutionalized people. Int J Vit Nutr Res 1984; 54: 185–193.

    CAS  Google Scholar 

  165. Pannemans DLE, Van den Berg H, Westerterp KR. The influence of protein intake on vitamin B-6 metabolism differs in young and elderly humans. J Nutr 1994; 124: 1207–1214.

    CAS  Google Scholar 

  166. Welling P. Nutrient effects on drug metabolism and action in the elderly. Drug-Nutr Interact 1985; 4: 173–207

    CAS  Google Scholar 

  167. Hartz SC. Proceedings: International conference on nutrients, medicines and aging. Drug-Nutr Interact 1985; 4: 3–263

    Google Scholar 

  168. Boullata JI, Barber JR. A perspective on drug–nutrient interactions. In: Boullata JI, Armenti VT, eds. Handbook of Drug–Nutrient Interactions. The Humana Press, Totowa, NJ, 2004, 3–25.

    Google Scholar 

  169. Malone M. Nutrition and the elderly. Pharmacy Times 1997; 55–63.

    Google Scholar 

  170. Miller CA. Drug/Food/Food supplements interactions. Geriatric Nursing 1999; 20 (3): 164–168.

    Article  CAS  Google Scholar 

  171. Schmidt LE, Dalhoff K. Food–drug interactions. Drugs 2002; 62 (10): 1481–502.

    Article  CAS  Google Scholar 

  172. Lisi DM. Potential food–drug interactions in a VA nursing home population. [abstract] J Am Geriatr Soc 1999; 47 (9): S98

    Google Scholar 

  173. Gauthier I, Malone M, Lesar TS, et al. Comparison of programs for preventing drug–nutrient interactions in hospitalized patients. Am J Health Syst Pharm 1997; 54 (4): 405–411.

    CAS  Google Scholar 

  174. Maka D, Murphy LK. Drug–nutrient interactions: a review. AACN 2000; 11 (4): 580–589.

    Article  CAS  Google Scholar 

  175. Boyd JA, Hospodka RJ, Bustamante P, et al. Nutritional considerations in the elderly. American Pharmacy 1991;NS31(4):45–50.

    Google Scholar 

  176. Chan LN. Drug–nutrient interaction in clinical nutrition. Curr Opin Clin Nutr Metab Care 2002; 5 (3): 327–332.

    Article  Google Scholar 

  177. Roe DA. Drug and nutrient interactions in the elderly diabetic. Drug-Nutr Interact 1988; 5: 195–203.

    CAS  Google Scholar 

  178. Roe DA. Drug and nutrient interactions in elderly cardiac patients. Drug-Nutr Interact 1988; 5: 205–212.

    CAS  Google Scholar 

  179. Barrick C, Connors GJ. Relapse prevention and maintaining abstinence in older adults with alcohol-use disorders. Drugs Aging 2002; 19 (8): 583–594.

    Article  Google Scholar 

  180. LCB-226.Alcohol Abuse and Older People: A Hidden Problem. Pennsylvania Liquor Control Board. 1998. http://www.lcb.state.pa.us/edu/

    Google Scholar 

  181. Rink A, Hays RD, Moore AA, et al. Alcohol-related problems in older persons: determinates, consequences and screening. Arch Intern Med 1996; 156 (11): 1150–1156.

    Article  Google Scholar 

  182. Ewing HA. Detecting alcoholism. The CAGE questionnaire. JAMA 1984; 252 (14): 1905–1907.

    Article  CAS  Google Scholar 

  183. Adams WL, Barry KL, Fleming MF. Screening for problem drinking in older primary care patients. JAMA 1996; 276 (24): 1964–1967.

    Article  CAS  Google Scholar 

  184. Moore AA, Seeman T, Morgenstern H, et al. Are there differences between older persons who screen positive on the CAGE questionnaire and the Short Michigan Alcoholism Screening Test-Geriatric version? J Am Geriatr Soc 2002; 50 (5): 858–862.

    Article  Google Scholar 

  185. Reid MC, Concato J, Rowle VR, et al. Alcohol use and functional disability among cognitively impaired adults. J Am Geriatr Soc 1999; 47: 854–859.

    CAS  Google Scholar 

  186. Miller CA. Caffeine, nicotine, and drugs. Geriatr Nurs 1996; 17 (1): 46–47.

    Article  CAS  Google Scholar 

  187. Carillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39 (2): 127–153.

    Article  Google Scholar 

  188. Kane GC, Lipsky JJ. Drug–grapefruit juice interactions. Mayo Clin Proc 2000; 75 (9): 933–942.

    Article  CAS  Google Scholar 

  189. Lilley LL, Guanci R. Grapefruit and medication. Am J Nurs 1998; 98 (12): 10.

    Google Scholar 

  190. Rodvold KA, Meyer J. Drug–food interactions with grapefruit juice. Infect Med 1996;13(10):868, 871–873, 912.

    Google Scholar 

  191. Spence DJ. Drug interactions with grapefruit: whose responsibility is it to warn the public? Clin Pharmacol Ther 1997; 61 (4): 395–400.

    Article  CAS  Google Scholar 

  192. Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice-felodipine interaction in the elderly. Clin Pharmacol Ther 2000; 68: 28–34.

    Article  CAS  Google Scholar 

  193. Byeth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized controlled trial. Ann Intern Med 2000; 133 (9): 687–695.

    Article  Google Scholar 

  194. O’Connell MB, Kowal PR, Allivato CJ, et al. Evaluation of warfarin initiation regimens in elderly inpatients. Pharmacotherapy 2000; 20 (8): 923–930.

    Article  Google Scholar 

  195. Gurwitz MJ, Rochon PA, Avorn J. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners. J Am Geriatr Soc 1997; 45 (9): 1060–1065.

    Google Scholar 

  196. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med 1994; 121 (9): 676–683.

    Article  CAS  Google Scholar 

  197. Blickstein D, Shalkai M, Inbal A. Warfarin antagonism by avacado. Lancet 1991; 337: 915.

    Article  Google Scholar 

  198. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health-Syst Pharm 1999; 56: 125–138.

    CAS  Google Scholar 

  199. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999; 59 (5): 1239–1244.

    CAS  Google Scholar 

  200. Winter ME. Phenytoin. In: Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics ( 3rd ed. ). Applied Therapeutics Inc, Vancouver, 1994, pp. 313–148.

    Google Scholar 

  201. Wilder BJ, Leppik I, Hietpas TJ, et al. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001; 57 (4): 582–589.

    Article  CAS  Google Scholar 

  202. Cook J, Randinitis E, Wilder BJ. Effect of food on the bioavailability of 100 mg Dilantin Kapseals. Neurology 2001; 57 (4): 698–700.

    Article  CAS  Google Scholar 

  203. Jacobson AF. Minimizing phenytoin and tube-feeding interactions. Am J Nurs 1998; 98 (6): 16.

    Article  Google Scholar 

  204. Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. J Parenter Enteral Nutr 1991; 15 (3): 316–318.

    Article  CAS  Google Scholar 

  205. Doak KK, Haas CE, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy 1998; 18 (3): 637–645.

    CAS  Google Scholar 

  206. Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy 1995; 15 (6): 801–805.

    CAS  Google Scholar 

  207. Lewis DP, VanDyke DC, Willhite LA, et al. Phenytoin-folic acid interactions. Ann Pharmacother 1995; 29 (7–8): 726–735.

    CAS  Google Scholar 

  208. Maxwell JD, Hunter J, Stewart DA, et al. Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? BMJ 1972; 1 (795): 297–299.

    Article  CAS  Google Scholar 

  209. Spray GH, Burns DG. Folate deficiency and anticonvulsant drugs. BMJ 1972; 2 (806): 167–168.

    Article  CAS  Google Scholar 

  210. Andreasen PB, Hansen JM, Skovsted L, et al. Folic acid and phenytoin metabolism. Lancet 1971; 1 (7700): 645.

    Article  CAS  Google Scholar 

  211. Baylis EM, Crowley JM, Preece JM, et al. Influence of folic acid on bood-phenytoin levels. Lancet 1971; 1 (7689): 62–64.

    Article  CAS  Google Scholar 

  212. Blain H, Hamdan KA, Blain A, et al. Aplastic anemia induced by phenytoin: a geriatric case with severe folic acid deficiency. J Am Geriatr Soc 2002; 50 (2): 396–397.

    Article  Google Scholar 

  213. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19 (4): 299–320.

    Article  CAS  Google Scholar 

  214. Cramer C. Hypertensive crisis from drug-food interaction. Am J Nurs 1997; 97 (5): 32.

    CAS  Google Scholar 

  215. Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 1998; 13 (5): 341–355.

    Article  CAS  Google Scholar 

  216. Fortes C, Forastiere F, Agabiti N, et al. The effect of zinc and vitamin A supplementation on immune response in an older population. J Am Geriatr Soc 1998; 46: 19–26.

    CAS  Google Scholar 

  217. Graat JM, Schouten EG, Kok FJ. Effect of daily vitamin E and multivitamin-mineral supplementation on acute respiratory tract infections in elderly persons: a randomized controlled trial. JAMA 2002; 288: 715–721.

    CAS  Google Scholar 

  218. Gold JL, Laxer D, Dergal JM, et al. Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care 2001; 4: 29–34.

    Article  CAS  Google Scholar 

  219. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19 (12): 911–927.

    Article  CAS  Google Scholar 

  220. Lazzaroni M, Bianchi PG. Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists. Drugs Agin. 1996; 9 (4): 251–261.

    Article  CAS  Google Scholar 

  221. Ruscin JM, Page RL, Valuck RJ. Vitamin B(12) deficiency associated with histamine (2)-receptor antagonists and a proton pump inhibitor. Ann Pharmacother 2002; 36 (5): 812–816.

    Article  Google Scholar 

  222. Andres E, Kaltenbach G, Perrin AE, et al. Food-cobalamin malabsorption in the elderly. Am J Med 2002; 113 (4): 351–352.

    Article  Google Scholar 

  223. Force RW, Meeker AD, Cady PS, et al. Increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003; 37: 490–493.

    Article  CAS  Google Scholar 

  224. Steinmetz KL. Colesevelam hydrochloride. Am J Health-Syst Pharm 2002; 59 (10): 932–939.

    CAS  Google Scholar 

  225. White R, Ashworth A. How drug therapy can affect, threaten, and compromise nutritional status. J Hum Nutr Diet 2000; 13 (2): 119–129.

    Article  Google Scholar 

  226. Schiller LR. The therapy of constipation. Aliment Pharmacol Ther 2001; 15 (6): 749–763.

    Article  CAS  Google Scholar 

  227. Tomkin GH, Hadden DR, Weaver JA, et al. Vitamin-B12 status of patients on long-term metformin therapy. BMJ 1971; 2: 685–687.

    Article  CAS  Google Scholar 

  228. Andres E, Noel E, Goichot B. Metformin-associated vitamin B12 deficiency. Arch Intern Med 2002; 162 (19): 2251–2252.

    Article  Google Scholar 

  229. Gilligan MA. Metformin and vitamin B12 deficiency. Arch Intern Med 2002; 162 (4): 484–485.

    Article  Google Scholar 

  230. Bauman WA, Shaw S, Jayatilleke E, et al. Diabetes Care 2000; 23 (9): 1227–1231.

    Article  CAS  Google Scholar 

  231. Eikelboom JW, Lonn E, Genest J, et al. Homocysteine and cardiovascular disease: a critical review of the epidemiology evidence. Ann Intern Med 1999; 131: 363–375.

    Article  CAS  Google Scholar 

  232. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham study. Ann Intern Med 1999; 131: 352–355.

    Article  CAS  Google Scholar 

  233. Campbell NRC, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med 1992; 117: 1010–1013.

    Article  CAS  Google Scholar 

  234. Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine by aluminum hydroxide. Arch Intern Med 1992; 152: 183–184.

    Article  CAS  Google Scholar 

  235. Liel Y, Sperber AD, Shany S. Nonspecific intestinal adsorption of levothyroxine by aluminum hydroxide. Am J Med 1994; 97: 363–365.

    Article  CAS  Google Scholar 

  236. Liel Y, Harman-Boehm I, Shany S. Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab 1996; 81: 857–859.

    Article  CAS  Google Scholar 

  237. Singh M, Singh PN, Herschman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA 2000; 283 (21): 2822–2825.

    Article  CAS  Google Scholar 

  238. Mersebach H, Rasmussen AK, Kirkegaard L, et al. Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol Toxicol 1999; 84 (3): 107–109.

    Article  CAS  Google Scholar 

  239. Fosamax prescribing information. Merck, Whitehouse Station, NJ, 2002.

    Google Scholar 

  240. Actonel prescribing information. Aventis Pharmaceuticals, Kansas City, MO, 2002.

    Google Scholar 

  241. Denman SJ. Esophagitis associated with the use of alendronate. J Am Geriatr Soc 1997; 45 (5): 662.

    Google Scholar 

  242. Cummings SR, Black DM, Thompson DE, et al. Affect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280 (24): 2077–2082.

    Article  CAS  Google Scholar 

  243. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study: a randomized, controlled trial. Ann Intern Med 1999; 131: 935–942.

    Article  CAS  Google Scholar 

  244. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999; 282 (14): 1344–1352.

    Article  CAS  Google Scholar 

  245. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333–340.

    Article  CAS  Google Scholar 

  246. Eriksson T, Granerus AK, Linde A, et al. “On–off” phenomenon in Parkinson’s disease: relationship between dopa and other large neutral amino acids in plasma. Neurology 1988; 38 (8): 1245–1248.

    Article  CAS  Google Scholar 

  247. Nutt JG, Woodward WR, Hammerstad JP, et al. Relation to levodopa absorption and transport. N Engl J Med 1984; 310 (8): 483–488.

    Article  CAS  Google Scholar 

  248. Olanow CW, Watts RL, Koller WC. An algorithm for the management of Parkinson’s disease: treatment guidelines. Neurology 2001; 56 (11): S1–S88.

    Article  CAS  Google Scholar 

  249. Juncos JL, Fabbrini G, Mouradian MM. Dietary influences on the antiparkinsonian reponse to levodopa. Arch Neurol 1987; 44 (10): 1003–1005.

    Article  CAS  Google Scholar 

  250. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 1994; 38 (9): 2101–2105.

    Article  CAS  Google Scholar 

  251. Wallace JI, Shwartz RS, LaCriox A, et al. Involuntary weight loss in older outpatients: incidence and clinical significance. J Am Geriatr Soc 1995; 43: 329–337.

    CAS  Google Scholar 

  252. Marton KI, Soc HC, Krupp JR, et al. Involuntary weight loss: diagnostic and prognostic significance. Ann Intern Med 1981; 95: 568–574.

    Article  CAS  Google Scholar 

  253. Pytlarz A. Medications and involuntary weight loss: looking beyond the obvious. Consult Pharm 2002;17(6):485–486, 488, 491–492, 494–495.

    Google Scholar 

  254. Miller LJ, Kwan RC. Pharmacological treatment of undernutrition in the geriatric patient. Consult Pharm 2002; 17: 739–747.

    Google Scholar 

  255. Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm 2000; 57: 238–258.

    CAS  Google Scholar 

  256. Wick JY. Drug-induced weight changes in residents of long-term care facilities. Consult Pharm 1998;13(12):1337–1340, 1343–1344, 1347–1348.

    Google Scholar 

  257. Carnahan RM, Lund BC, Perry PJ. Ziprasidone, a new atypical antipsychotic drug. Pharmacotherapy 2001; 21 (6): 717–730.

    Article  CAS  Google Scholar 

  258. Conley R, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2001; 158: 765–774.

    Article  CAS  Google Scholar 

  259. Maixner SM, Mellow Am, Tandon R. The efficacy, safety and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999; 60: S29–S41.

    Article  Google Scholar 

  260. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–1696.

    CAS  Google Scholar 

  261. Stimmel G, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17 (1): 10–21.

    CAS  Google Scholar 

  262. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability or mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int Clin Psychopharmacol 1999; 14 (6): 329–337.

    Article  CAS  Google Scholar 

  263. Remuron prescribing information. Organon, West Orange, NJ, 2001.

    Google Scholar 

  264. Holt RA, Maunder EMW. Is lithium-induced weight gain prevented by providing healthy eating advice at the commencement of lithium therapy? J Hum Nutr Diet 1996; 9 (2): 127–133.

    Article  Google Scholar 

  265. Chen Y, Silverstone T. Lithium and weight gain. Intt Clin Psychopharmacol 1990; 5 (3): 217–225.

    Article  CAS  Google Scholar 

  266. Monane M, Gurwitz J, Bohn R, et al. The impact of thiazide diuretics on the initiation of lipid-reducing agents in older people: a population-based analysis. J Am Geriatr Soc 1997; 45 (1): 71–75.

    CAS  Google Scholar 

  267. Guay DRP. Hynonatremia associated with selective serotonin reuptake inhibitors. Consult Pharm 2000; 15 (2): 160–177.

    Google Scholar 

  268. Booker JA. Severe symptomatic hyponatremia in elderly outpatients: the role of thiazide therapy and stress. J Am Geriatr Soc 1984; 32 (2): 108–113.

    CAS  Google Scholar 

  269. Kugler JP, Hustead T. Hyponatremia and hypernatremia in the elderly. Am Fam Physician 2000; 61: 3623–3630.

    CAS  Google Scholar 

  270. Christe C, Vogt N. SSRI-induced SIADH in older people. J Am Geriatr Soc 1999; 47 (5): 630–631.

    CAS  Google Scholar 

  271. Spigset O, Hedenmalm K. Hyponatremia in relation to treatment with antidepressants: a survey of reports in the World Health Organization data base for spontaneous reporting of adverse drug events. Pharmacotherapy 1997; 17 (2): 348–352.

    CAS  Google Scholar 

  272. Odeh M, Beny A, Oliven A. Severe hyponatremia during citalopram therapy. [abstract] Am J Med Sci 2001; 321: 159–160.

    Article  CAS  Google Scholar 

  273. Miyaoka R, Seno H, Itoga M, et al. Contribution of sodium valproate to the syndrome of inappropriate antidiuretic hormone. [abstract] Int Clin Psychopharmacol 2001; 16: 59–61.

    Article  CAS  Google Scholar 

  274. Shaikh ZH, Taylor HC, Maroo PV, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. [abstract] Ann Pharmacother 2000; 334: 176–179.

    Google Scholar 

  275. van Assen S, Muddle AH. Severe hyponatremia in an amiloride/hydrochlorothiazide-treated patient. [abstract] Neth J Med 1999; 54: 108–113.

    Article  Google Scholar 

  276. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342 (21): 1581–1589.

    Article  CAS  Google Scholar 

  277. Tolstoi LG. Drug-induced hyperkalemia. Hosp Pharm 1996; 31 (3): 221–228.

    Google Scholar 

  278. Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med 1998; 158 (1): 26–32.

    Article  CAS  Google Scholar 

  279. Chew M, Bult J, Schiff G. Drug-induced hyperkalemia. Hosp Pharm 2001;36(6):684,687.

    Google Scholar 

  280. Wehring H, Alexander B, Perry PJ. Diabetes mellitus associated with clozapine therapy. Pharmacotherapy 2000; 20 (7): 844–847.

    Article  CAS  Google Scholar 

  281. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999; 60: 556–557.

    Article  CAS  Google Scholar 

  282. Lindenmayer JP, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus. Am J Psychiatry 1999; 156 (9): 1471.

    CAS  Google Scholar 

  283. Ober S, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. [letter] Am J Psychiatry 1999; 156 (6): 970.

    CAS  Google Scholar 

  284. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999; 22 (6): 1002–1003.

    Article  CAS  Google Scholar 

  285. HedenmalmK, Hagg S, Stahl M, et al. Glucose intolerance with atypical antipsychotics. Drug Saf 2002; 25 (15): 1107–1116.

    Google Scholar 

  286. http://www.fda.gov/cber/guidelines.htm Guidance for Industry. Content and Format for Geriatric Labeling. October 2001. Accessed 10/7/02

  287. http://www.fda.gov Guideline for Industry: Studies in Support of Special Populations: Geriatrics. August 1994. Accessed 10/7/02

  288. http://www.Fda.gov/oashi/patrep/demo.html. Investigational New Drug Applications and New Drug Applications: Final Rule. 21 CFR parts 312 and 314. No. 95N-0010. Accessed 10/7/02

    Google Scholar 

  289. http://www. fda.gov. Draft guidance: In Vivo Drug Metabolism/Drug Interaction Studies- Study Design, Data Analysis, and Recommendations for Dosing and Labeling. November 1998. Accessed 10/7/02.

    Google Scholar 

  290. Owens NJ, Silliman RA, Fretwell MD. The relationship between comprehensive functional assessment and optimal pharmacotherapy in the older patient. DICP 1989; 23: 847–853.

    CAS  Google Scholar 

  291. Comprehensive functional assessment for elderly patients: health and public policy committee. Ann Intern Med 1988;70–72.

    Google Scholar 

  292. Miller KE, Zylstra RG, StandridgeJB. The geriatric patient: a systematic approach to maintaining health. Am Fam Physician 2000; 61 (4): 1089–1104.

    CAS  Google Scholar 

  293. ASHP guidelines on the pharmacist’s role in home care. Am J Health-Syst Pharm 2000; 57 (13): 1252–1257.

    Google Scholar 

Download references

Authors
  1. Tanya C. Knight-Klimas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph I. Boullata
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA, USA

    Joseph I. Boullata PharmD, BCNSP

  2. Department of Surgery, Temple University School of Medicine, Philadelphia, PA, USA

    Vincent T. Armenti MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Knight-Klimas, T.C., Boullata, J.I. (2004). Drug-Nutrient Interactions in the Elderly. In: Boullata, J.I., Armenti, V.T. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-781-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-781-9_20

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5359-2

  • Online ISBN: 978-1-59259-781-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation